US FDA approves expanded indication for AbbVie’s oral migraine therapy
Pharmaceutical Technology
APRIL 18, 2023
The US Food and Drug Administration (FDA) has granted approval for the expanded indication of AbbVie ’s Qulipta (atogepant) as a preventive treatment for chronic migraines in adult patients. Qulipta received approval to treat migraine across frequencies, including both episodic and chronic.
Let's personalize your content